Cardiac channelopathy testing in 274 ethnically diverse sudden unexplained deaths
Introduction
Sudden unexplained death (SUD) in apparently healthy individuals presents vexing challenges for medical examiners and still remains an important public health priority. SUD is defined by a cause of death which remains unknown after complete autopsies, comprehensive laboratory testing, review of all available history, and performance of a comprehensive scene investigation. According to the Centers for Disease Control and Prevention, more than 4500 infants die suddenly each year in the United States with no immediate or obvious cause of death; half of those deaths remain unexplained after a forensic investigation. Furthermore, the prevalence of sudden unexplained deaths beyond infancy (1ā22 years old) is also estimated to be greater than 2000 annually in the United States [1]. Despite a decline in SUD rates over the past decade, the rates are still disproportionately high amongst certain population groups, especially in African Americans and American Indian/Alaska Natives [2].
It is estimated that 10ā35% [3], [4], [5], [6], [7], [8] of SUD may be explained by cardiac channelopathies, which affect heart rhythm and cardiac electrical conduction physiology. These disorders comprise of a group of inheritable cardiac arrhythmia syndromes, such as long QT syndrome, catecholaminergic polymorphic ventricular tachycardia (CPVT), Brugada syndrome, and short QT syndrome. Despite extensive attempts at developing nationalized standards in SUD investigation including the establishment of basic guidelines [9], [10], currently, wide variation exists across the United States when investigating and certifying SUD [11]. Unfortunately, the use of molecular diagnostics is not commonly made as part of the medical investigation of SUD cases. The situation in European countries is also similar, with the application of genetic testing in routine forensic investigations being very limited [12]. Nevertheless, the New York City (NYC) Office of Chief Medical Examiner (OCME) has routinely integrated molecular testing of six major cardiac channelopathy genes (KCNQ1, KCNH2, SCN5A, KCNE1, KCNE2, and RyR2) in SUD investigations since 2008. This testing panel is significant for over 80% of the long QT syndromes, 25% of Brugada syndrome, and 50% of catecholaminergic polymorphic ventricular tachycardia (CPVT) [13].
The main goal of this study is to evaluate the significance of cardiac channelopathies in SUD within a large and ethnically diverse population from a single urban medical examiner's office in the United States.
Section snippets
Study cohort
Biological samples from a total of 340 cases of sudden unexpected natural death were submitted to the Molecular Genetics Laboratory in the New York City OCME for cardiac channelopathy testing from 2008 to 2012. Of those cases, 66 cases were excluded from this study based on the following criteria: (1) only an external examination was performed (often due to religious objection to autopsy), and (2) the causes of deaths were explained by autopsy or forensic laboratory findings. Based on this, 274
Unique demographic characteristics of the study cohort
The demographic characteristics of the 274 sudden unexplained deaths (SUD) investigated by the NYC OCME are summarized in Table 1. These 274 cases were divided into two age groups: infants (ā¤1 year old, 141 cases) and non-infants (>1 year old, 133 cases). In infants, 92.9% were younger than 6 months. In non-infants, 78.2% were older than 18 years old (the oldest decedent was 58 years old). African American is the leading ethnicity observed in both infants (60.3%) and non-infants (35.3%). While
Discussion
We present data from a comprehensive postmortem evaluation of 274 sudden unexplained deaths in New York City. Here we discuss the unique characteristics of the cohort, principal findings from this study, the benefits of molecular testing to the at-risk family members, and the challenges of the postmortem molecular diagnostics along with the limitations of this study.
Source of funding
This project was partially supported by Awards no. 2009-CD-BX-0049 and 2011-DN-BX-K535, awarded by the National Institute of Justice, Office of Justice Programs, U.S. Department of Justice.
Conflict of interest statement
There is no conflict of interest to be disclosed for any author on this paper.
Acknowledgement
We thank Dr. Jason K. Graham for critical review of this manuscript.
References (45)
- et al.
Postmortem molecular screening in unexplained sudden death
J. Am. Coll. Cardiol.
(2004) - et al.
Posthumous diagnosis of long QT syndrome from neonatal screening cards
Heart Rhythm
(2010) - et al.
Prospective, population-based long QT molecular autopsy study of postmortem negative sudden death in 1ā40 year olds
Heart Rhythm
(2011) - et al.
Postmortem long QT syndrome genetic testing for sudden unexplained death in the young
J. Am. Coll. Cardiol.
(2007) - et al.
Cardiac channel molecular autopsy: insights from 173 consecutive cases of autopsy-negative sudden unexplained death referred for postmortem genetic testing
Mayo Clin. Proc.
(2012) - et al.
ACMG recommendations for standards for interpretation and reporting of sequence variations: revisions 2007
Genet. Med.
(2008) - et al.
Compendium of cardiac channel mutations in 541 consecutive unrelated patients referred for long QT syndrome genetic testing
Heart Rhythm
(2005) - et al.
KCNE2 modulation of Kv4.3 current and its potential role in fatal rhythm disorders
Heart Rhythm
(2010) Cardiovascular disease 2005--the global picture
Vasc. Pharmacol.
(2006)- et al.
Targeted mutational analysis of the RyR2-encoded cardiac ryanodine receptor in sudden unexplained death: a molecular autopsy of 49 medical examiner/coroner's cases
Mayo Clin. Proc.
(2004)